Codeine is a popular opioid prodrug dependent on the activity of the specific cytochrome P450 enzyme 2D6 (CYP2D6). This enzyme catalyses the production of the potent analgesic metabolite morphine, but genetic studies have demonstrated that individuals from different ethnic groups exhibit considerable variability in the functional capacities of their expressed CYP2D6 enzymes, and pharmacological studies have shown many commonly prescribed drugs can reduce the action of CYP2D6 enzymes. These findings have significant clinical implications for the rational prescription of effective analgesia, especially in a multicultural country like Australia.
Top 10 drugs.Australian Prescriber Aust Prescrib1999; 22: 119.
2.
SanfilippoG.Contributo spermentaie all'ipotesi della smetilazione della codeina nell'organismo. 1) Influenza della dose sull'assuefazione alla codeina. II) Assuefazione alla codeina ottenuta consomministazione prolungata di morfina.Bollettino Societa Italiana Biologia Sperimentale1948; 24: 723–726.
3.
PertC.B., SnyderS.H.Properties of opiate-receptor binding in rat brain.Proc Natl Acad Sci1973; 70: 2243–2247.
4.
RaffaR.B., FriderichsE., ReimannW.. Complementary and synergistic antinociceptive interaction between the enan-tiomers of tramadol.Pharmacol Exp Ther1993; 267: 311–340.
5.
NeilA.Affinities of some common opioid analgesics towards four binding sites in mouse brain.Naunyn-Schmeideberg's Arch Pharmacol1984; 328: 24–29.
6.
ChenZ.R., IrvineR.J., SomogyiA.A., BochnerF.Mu receptor binding of some commonly used opioids and their metabolites.Life Science1991; 48: 2165–2171.
van der WeideJ., SteijnsL.Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology.Ann Clin Biochem1999; 36: 722–729.
9.
Ingelman-SundbergM., OscarsonM., McLellanR.Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment.Trends Pharmacol Sci1999; 20: 342–349.
10.
ChangG., KamP.The physiological and pharmacological roles of cytochrome P450 isoenzymes.Anaesthesia1999; 54: 42–50.
11.
CaracoY., ShellerJ., WoodA.J.Pharmacogenetic determination of the effects of codeine and prediction of drug interactions.J Pharmacol Exp Ther1996; 278: 1165–1174.
12.
SindrupS., BrosenK.The pharmacogenetics of codeine hypo-algesia.Pharmacogenetics1995; 5: 335–346.
13.
HedenmalmK., SundgrenM., GranbergK., SpigsetO., DahlqvistR.Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activity.Ther Drug Monit1997; 19: 643–649.
14.
OttonS., SchadelM., CheungS.. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromor-phone.Clin Pharmacol Ther1993; 54: 463–472.
15.
HeiskanenT., OlkkolaK.T., KalsoE.Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.Clin Pharmacol Ther1998; 64: 603–611.
16.
PoulsenL., Arendt-NielsenL., BrosenK., SindrupS.The hypoalgesic effect of tramadol in relation to CYP2D6.Clin Pharmacol Ther1996; 60: 636–644.
17.
Australian Bureau of Statistics Website.http://www.abs.gov.au/ Commonwealth Government of Australia 2000.
18.
RobiquetR.Neue beobachtungen, ber die vorz, glivhsten pro-dukte aus dem opium.Annalen der Pharmacie1833; 5: 82–111.
ReisineT., PasternakG.Opioid analgesics and antagonists. In: HardmanJ.G., LimbirdL.E. eds. Goodman & Gilman's The pharmacological basis of therapeutics.9th Ed.McGraw-Hill, New York1996.
21.
OberstF.W.Relationship of the chemical structure of morphine derivatives to their urinary excretion in free and bound forms.J Pharmacol Exp Ther1941; 73: 401–404.
22.
AdlerT.K., FujimotoJ.M., LeongW.E., BakerE.M.The metabolic fate of codeine in man.J Pharmacol Exp Ther1955; 114: 251–262.
23.
DayerP., DesmeulesJ., LeemannT., StriberniR.Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI).Biochem Biophys Res Commun1988; 152: 411–416.
24.
ChenZ., SomogyiA., BochnerF.Polymorphic O-demethylation of codeine.Lancet1988; 2: 914–915.
HaslerJ.Pharmacogenetics of cytochromes P450.Mol Aspects Med1999; 20: 12–24, 25–137.
27.
GilhamD., CairnsW., PaineM.. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization.Xenobiotica1997; 27: 111–125.
LadonaM., LindstromB., ThyrC., Dun-RenP., RaneA.Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man.Br J Clin Pharmacol1991; 32: 295–302.
30.
YueQ., TomsonT., SaweJ.Carbamazepine and cigarette smoking induce differentially the metabolism of codeine in man.Pharmacogenetics1994; 4: 193–198.
31.
FishmanJ., HahnE.F., NortonB.I.N-demethylation of morphine in rat brain is located in sites with high opiate receptor content.Nature1976; 261: 64–65.
32.
PoulsenL., RiishedeL., BrosenK., ClemensenS., SindrupS.Codeine in post-operative pain. Study of the influence of sparteine phenotype and serum concentrations of morphine and morphine-6-glucuronide.Eur J Clin Pharmacol1998; 54: 451–454.
33.
YueQ., HasselstromJ., SvenssonJ., SaweJ.Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine.Br J Clin Pharmacol1991; 31: 635–642.
34.
OsborneR., JoelS., TrewD., SlevinM.Analgesic activity of morphine-6-glucuronide.Lancet1988; 1: 828.
35.
PaulD., StandiferK., InturrisiC., PasternakG.Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite.J Pharmacol Exp Ther1989; 251: 477–483.
36.
AderjanR., SkoppG.Formation and clearance of active and inactive metabolites of opiates in humans.Ther Drug Monit1998; 20: 561–569.
37.
OsborneR., JoelS., TrewD., SlevinM.Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite mor-phine-6-glucuronide.Clin Pharmacol Ther1990; 47: 12–19.
38.
PortenoyR., FoleyK., StulmanJ.. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure.Pain1991; 47: 13–19.
39.
PortenoyR., ThalerH., InturrisiC., Friedlander-KlarH., FoleyK.The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function.Clin Pharmacol Ther1992; 51: 422–431.
40.
KlepstadP.Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from mor-phine-6-glucuronide to the analgesia produced by morphine.Eur J Clin Pharmacol2000; 55: 713–719.
41.
JochimsenP., NoyesR.J.Appraisal of codeine as an analgesic in older patients.J Am Geriatr Soc1978; 26: 521–523.
42.
HonigS., MurrayK.An appraisal of codeine as an analgesic: single-dose analysis.J Clin Pharmacol1984; 24: 96–102.
43.
QuidingH., LundqvistG., BoreusL.O., BondessonU., OhrvikJ.Analgesic effect and plasma concentrations of codeine and morphine after two dose levels of codeine following oral surgery.Eur J Clin Pharmacol1993; 44: 319–323.
44.
GuayD., AwniW., HalstensonC.. Pharmacokinetics of codeine after single- and multiple-oral-dose administration to normal volunteers.J Clin Pharmacol1987; 27: 983–987.
45.
OldendorfW.H., HymanS., BraunL., OlendorfS.Z.Blood-Brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection.Science1972; 178: 984–986.
46.
GuidiceJ.M., MarezD., SabbaghN.. Evidence for CYP2D6 expression in human lung.Biochem Biophys Res Commun1997; 241: 79–85.
47.
ElisonC., ElliottH.W.N- and O-demethylation of some narcotic analgesics by brain slices from male and female Long-Evans rats.Biochem Pharmacol1963; 12: 1363–1366.
48.
ChenZ., IrvineR., BochnerF., SomogyiA.Morphine formation from codeine in rat brain: a possible mechanism of codeine analgesia.Life Sci1990; 46: 1067–1074.
49.
TyndaleR.F., LiY., LiN.Y.. Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan.Drug Metab Dispos1999; 27: 924–930.
50.
SindrupS.H., Arendt-NielsenL., BrosenK.. The effect of quinidine on the analgesic effect of codeine.Eur J Clin Pharmacol1992; 42: 587–591.
51.
FindlayJ.W.A., JonesE.C., ButzR.F., WelchR.M.Plasma codeine and morphine concentrations after therapeutic oral doses of codeine containing analgesics.Clin Pharmacol Ther1978; 24: 66–68.
52.
RogersJ., FindlayJ., HullJ.. Codeine disposition in smokers and nonsmokers.Clin Pharmacol Ther1982; 32: 218–227.
53.
BradfordL., GaedigkA., LeederJ.High frequency of CYP2D6 poor and “intermediate” metabolizers in black populations: a review and preliminary data.Psychopharmacol Bull1998; 34: 797–804.
54.
ZangerU.M., EichelbaumM.Chapter 8. CYP2D6. In: LevyR.H., ThummelK.E., HansteinP.D., EichelbaumM., eds. Metabolic drug interactions.Lippincott Williams & Wilkins, Philadelpia, USA2000; 87–94.
55.
WennerholmA., JohanssonI., MasseleA.Y.. Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype.Pharmacogenetics1999; 9: 707–714.
56.
BathumL., SkjelboE., MutabingwaT.K.. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.Br J Clin Pharmacol1999; 48: 395–401.
57.
JorgeL.F., EichelbaumM., GrieseE.U., InabaT., AriasT.D.Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations.Pharmacogenetics1999; 9: 217–228.
58.
PanseratS., SicaL., GerardN.. CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype.Br J Clin Pharmacol1999; 47: 121–124.
59.
LeathartJ.B., LondonS.J., StewardA.. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles.Pharmacogenetics1998; 8: 529–541.
60.
HeN., DanielH., HajilooL., ShockleyD.Dextromethorphan O-demethylation polymorphism in an African-American population.Eur J Clin Pharmacol1999; 55: 457–459.
61.
MasimirembwaC., HaslerJ., BertilssonsL.. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs.Eur J Clin Pharmacol1996; 51: 117–122.
62.
DalyA.K., ArmstrongM., MonkmanS.C., IdleM.E., IdleJ.R.Genetic and metabolic criteria for the assignment of debriso-quine 4-hydroxylation (cytochrome P4502D6) phenotypes.Pharmacogenetics1991; 1: 33–41.
63.
SachseC., BrockmollerJ., BauerS., RootsI.Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.Am J Hum Genet1997; 60: 284–295.
64.
BrolyF., GaedigkA., HeimM.. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.DNA Cell Biol1991; 10: 545–558.
65.
PoulsenL., BrosenK., Arendt-NielsenL.. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects.Eur J Clin Pharmacol1996; 51: 289–295.
66.
CaracoY., ShellerJ., WoodA.J.Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects.J Pharmacol Exp Ther1999; 290: 413–422.
67.
YueQ., AlmC., SvenssonJ., SaweJ.Quantification of the O-and N-demethylated and the glucuronidated metabolites of codeine relative to the debrisoquine metabolic ratio in urine in ultrarapid, rapid, and poor debrisoquine hydroxylators.Ther Drug Monit1997; 19: 539–542.
68.
YueQ., IseliusL., SaweJ.Indices and graphical approaches for the detection of interindividual and interethnic variations in codeine metabolism.Br J Clin Pharmacol1997; 44: 239–244.
69.
DrollK., Bruce-MensahK., OttonS.. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.Pharmacogenetics1998; 8: 325–333.
70.
MasimirembwaC., HaslerJ.Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants.Brain Res Bull1997; 44: 561–571.
71.
SohnD-R, ShinS-G, ParkC-W, KusakaM., ChibaK., IshizakiT.Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations.J Clin Pharmacol1991; 32: 504–507.
72.
YueQ., SvenssonJ., SaweJ., BertilssonL.Codeine metabolism in three Oriental populations: a pilot study in Chinese, Japanese and Koreans.Pharmacogenetics1995; 5: 173–177.
73.
DalenP., FrengellC., DahlM., SjoqvistF.Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine.Ther Drug Monit1997; 19: 543–544.
74.
BernalM.L., SinuesB., JohanssonI.. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine.Pharmacogenetics1999; 9: 657–660.
75.
McLellanR., OscarsonM., SeidegardJ., EvansD., Ingelman-SundbergM.Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians.Pharmacogenetics1997; 7: 187–191.
76.
AynaciogluA., SachseC., BozkurtA.. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.Clin Pharmacol Ther1999; 66: 185–192.
77.
AklilluE., PerssonI., BertilssonL.. Frequent distrubution of untrarapid metabolisers of debrisoquinine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.J Pharmacol Exp1996; 278: 441–444.
78.
DalenP., DahlM., AnderssonK., BertilssonL.Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.Br J Clin Pharmacol2000; 49: 180–184.
79.
BellwoodP.S.The Polynesians.Thames and Hudson, London1987.
80.
MeltonT., PetersonR., ReddA.J.. Polynesian genetic affinities with South-East Asian populations as identified by mtDNAanalysis.Am J Human Genetics1995; 57: 403–414.
81.
FlanneryT.F.The Future Eaters.An ecological history of the Australasian lands and peoples.Reed Books, Kew, Victoria, Australia1997.
82.
WanwimolrukS., BhawanS., CovilleP., ChalcroftS.Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.Eur J Clin Pharmacol1998; 54: 431–435.
83.
IlettK.F., GrieseE-U, EichelbaumM.. Genetic polymorphisms in CYP2D6, CYP2C19 and CYP2E1 in an Australian aborigine population. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Sydney, December 7–9 19996; 131: 2–21.
84.
WanwimolrukS., PrattE., DentonJ.. Evidence for the polymorphic oxidation of debrisoquine and proguanil in a New Zealand Maori population.Pharmacogenetics1995; 5: 193–198.
85.
YueQ., SvenssonJ., AlmC., SjoqvistF., SaweJ.Interindividual and interethnic differences in the demethylation and glucuronidation of codeine.Br J Clin Pharmacol1989; 28: 629–637.
86.
CaracoY., ShellerJ., WoodA.Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.J Pharmacol Exp Ther1997; 281: 330–336.
87.
AdedoyinA., ArnsP., RichardsW., WilkinsonG., BranchR.Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.Clin Pharmacol Ther1998; 64: 8–17.
88.
KashubaA., NafzigerA., KearnsG.. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping.Pharmacogenetics1998; 8: 403–410.
89.
WadeliusM., DarjE., FrenneG., RaneA.Induction of CYP2D6 in pregnancy.Clin Pharmacol Ther1997; 62: 400–407.
90.
EreshefskyL., RiesenmanC., LamY.Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.Clin Pharmacokinet1995; 29 Suppl 1: 10–18; Discussion 18–19.
91.
WuD., OttonS., SprouleB.. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.Br J Clin Pharmacol1993; 35: 30–34.
92.
Abdel-RahmanS.M., GotschallR.R., KauffmanR.E., LeederJ.S., KearnsG.L.Investigation of terbinafine as a CYP2D6 inhibitor in vivo.Clin Pharmacol Ther1999; 65: 465–472.
93.
DayerP., DesmeulesJ., StriberniR.In vitro forecasting of drugs that may interfere with codeine bioactivation.Eur J Drug Metab Pharmacokinet1992; 17: 115–120.
94.
SindrupS., HofmannU., AsmussenJ.. Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake.Eur J Clin Pharmacol1996; 49: 503–509.
95.
de GrootM.J., AcklandM.J., HorneV.A., AlexA.A., JonesB.C.Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6.J Med Chem1999; 42: 1515–1524.
96.
HasselstromJ., YueQ., SaweJ.The effect of codeine on gastrointestinal transit in extensive and poor metabolisers of debrisoquine.Eur J Clin Pharmacol1997; 53: 145–148.
97.
EckhardtK., LiS., AmmonS.. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation.Pain1998; 76: 27–33.
98.
MikusG., TrauschB., RodewaldC.. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype.Clin Pharmacol Ther1997; 61: 459–466.
RomachM.K., OttonS.V., SomerG., TyndaleR.F., SellersE.M.Cytochrome P450 2D6 and treatment of codeine dependence.J Clin Psychopharmacol2000; 20: 43–45.
101.
TegederI., LotschJ., GeisslingerG.Pharmacokinetics of opioids in liver disease.Clin Pharmacokinet1999; 37: 17–40.
102.
BertilssonL.Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.Clin Pharmacokinet1995; 29: 192–209.
103.
BachusR., BickelU., ThomsenT., RootsI., KewitzH.The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6.Pharmacogenetics1999; 9: 661–668.
